<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information for the period ended March
31, 1996, restated to reflect the combined results of Incyte Pharmaceuticals,
Inc. and Synteni, Inc.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000
       
                             
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               MAR-31-1996
<CASH>                                          12,638
<SECURITIES>                                    36,558
<RECEIVABLES>                                      473
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                50,881
<PP&E>                                          16,329
<DEPRECIATION>                                   4,339
<TOTAL-ASSETS>                                  63,311
<CURRENT-LIABILITIES>                           17,099
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            22
<OTHER-SE>                                      45,333
<TOTAL-LIABILITY-AND-EQUITY>                    63,311
<SALES>                                              0
<TOTAL-REVENUES>                                 6,274
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                 7,839
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (2,086)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (2,086)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (2,086)
<EPS-PRIMARY>                                   (0.09)
<EPS-DILUTED>                                   (0.09)